Aeterna Zentaris (NASDAQ:AEZS) Research Coverage Started at StockNews.com
by Amy Steele · The Cerbat GemStockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
Shares of NASDAQ AEZS opened at $3.90 on Friday. The stock has a market capitalization of $7.00 million, a price-to-earnings ratio of -0.26 and a beta of 1.55. The firm’s 50 day simple moving average is $5.11 and its 200-day simple moving average is $6.64. Aeterna Zentaris has a 12 month low of $3.96 and a 12 month high of $12.00.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
- Five stocks we like better than Aeterna Zentaris
- Industrial Products Stocks Investing
- The Average 401k Balance by Age Explained
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- How to Invest in Biotech Stocks
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now